Table 1. Association between miR-199b and clinical and molecular parameters in 97 patients with metastatic CRC.
| No. Cases | High miR-199b (%) | Low miR-199b (%) | P | |
|---|---|---|---|---|
| miR-199b | 97 | 73 (75.3) | 24 (24.7) | |
| Sex | 97 | 73 | 24 | 0.830 |
| Male | 67 | 50 (74.6) | 17 (25.4) | |
| Female | 30 | 23 (76.7) | 7 (23.3) | |
| Age | 93 | 71 | 22 | 0.079 |
| < 70 | 44 | 30 (68.2) | 14 (31.8) | |
| ≥ 70 | 49 | 41 (83.7) | 8 (16.3) | |
| ECOG | 92 | 71 | 21 | 0.175 |
| 0–2 | 75 | 60 (80) | 15 (20) | |
| 3–4 | 17 | 11 (64.7) | 6 (35.3) | |
| Site of primary tumor | 97 | 73 | 24 | 0.524 |
| Colon | 72 | 53 (73.6) | 19 (26.4) | |
| Rectum | 25 | 20 (80) | 5 (20) | |
| Synchronous metastasis | 97 | 73 | 24 | 0.026 |
| No | 39 | 34 (87.2) | 5 (12.8) | |
| Yes | 58 | 39 (67.2) | 19 (32.8) | |
| Number of metastatic sites | 97 | 73 | 24 | 0.383 |
| 1–2 | 89 | 68 (76.4) | 21 (23.6) | |
| > 2 | 8 | 5 (62.5) | 3 (37.5) | |
| Liver metastasis | 97 | 73 | 24 | 0.282 |
| No | 33 | 27 (81.8) | 6 (18.2) | |
| Yes | 64 | 46 (71.9) | 18 (28.1) | |
| Lung metastasis | 97 | 73 | 24 | 0.264 |
| No | 68 | 49 (84.5) | 19 (15.5) | |
| Yes | 29 | 24 (82.8) | 5 (17.2) | |
| Lymph metastasis | 97 | 73 | 24 | 0.049 |
| No | 68 | 55 (80.9) | 13 (19.1) | |
| Yes | 29 | 18 (62.1) | 11 (37.9) | |
| Peritoneal metastasis | 97 | 73 | 24 | 0.173 |
| No | 78 | 61 (78.2) | 17 (21.8) | |
| Yes | 19 | 12 (63.2) | 7 (36.8) | |
| MSI | 95 | 71 | 24 | 0.617 |
| No | 89 | 66 (74.2) | 23 (25.8) | |
| Yes | 6 | 5 (83.3) | 1 (16.7) | |
| KRAS mutated | 97 | 73 | 24 | 0.755 |
| No | 58 | 43 (74.1) | 15 (25.9) | |
| Yes | 39 | 30 (76.9) | 9 (23.1) | |
| SET overexpression | 97 | 73 | 24 | < 0.001 |
| No | 65 | 58 (89.2) | 7 (10.8) | |
| Yes | 32 | 15 (46.9) | 17(53.1) |